Compare Broadcom Inc (AVGO) vs Cronos Group Inc (CRON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Broadcom Inc vs Cronos Group Inc — how do they compare? Broadcom Inc trades at $419.75 (market cap $1.98T), while Cronos Group Inc trades at $3.08 (market cap $1.14B). The key difference: Broadcom Inc is far larger — about 1736.8× Cronos Group Inc's market cap, and Broadcom Inc pays a 0.62% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| AVGO | CRON | |
|---|---|---|
Market Cap | $1.98T | $1.14B |
Sector | Technology | Health |
52-Week High | $481.57 | $3.27 |
52-Week Low | $289.60 | $2.30 |
Enterprise Value | $2.02T | $341.13M |
Dividend Yield | 0.62% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →
